ESG Report 2024

4 03 About Us In 2024, The United Laboratories, will continue to cooperate with all parties to fulfil its mission of safeguarding human health. Against the backdrop of the deepening reform of the medical and healthcare system in recent years, The United Laboratories has been adhering to the research and development (R&D) philosophy of “Pragmatic and Rigorous, Scientific and Truth-seeking, Future-focused and Innovative”, and has continued to cultivate a team of top-notch talents, increase investment in research and development, and promote the innovation of products and technologies. Through a scientific and efficient management system, we will comprehensively improve the quality of our products and services, and with the spirit of pursuing excellence, we will push The United Laboratories towards a new stage of high-quality and sustainable development. The United Laboratories continues to focus on its core business of R&D, production and sales of pharmaceutical products, including finished products, bulk medicines intermediate products, veterinary drugs, pharmaceutical capsules and medical devices, forming a diversified and relatively complete product portfolio. We insist on satisfying people's health needs as our responsibility. Close attention is paid to new molecules and cutting-edge technologies in the field of global new drug R&D. Based on our clinical value and differentiation strategy, we have made forward-looking investments in innovative drugs and high-barrier complex preparations. Continuous promotion of product innovation and upgrades occurs, while high-quality products and services are regularly introduced. These efforts aim to accelerate the establishment of a health protection barrier for the entire population. In order to better respond to the national call, we are constantly striving to enhance the accessibility and affordability of pharmaceutical products to achieve the strategic goal of “Comprehensively Promoting the Construction of a Healthy China”. In view of the differences in economic development across various regions in overseas markets, we have formulated an equitable pricing policy which aligns with the income levels of local communities and is aimed at providing high-quality medicines at affordable prices. The goal is to alleviate the burden of medical treatment on local populations and reduce health disparities in resource-poor regions. In addition, we are committed to expanding our international business and expanding the exposure to the medical insurance and essential drugs lists to further enhance access to medicines. We have joined the National Centralised Procurement Scheme for Pharmaceutical Products to effectively reduce the cost of medicines for patients, and have actively participated in high-level academic forums and conferences on pharmaceuticals to promote the advancement of global healthcare standards. The Group regards employees as the core pillar of corporate development and deeply understands the critical role of talents in the success of the Group. Adhering to the “People-Oriented” principle, the Group ensures the safety, health, and legal rights of employees while creating a diverse training and development system. This system helps employees at all levels enhance their professional skills and comprehensive abilities, achieving growth alongside the Group. We attach great importance to the physical and mental health of our employees. Through organising a wide range of activities, we help them achieve work-life balance and enhance their sense of belonging. We adhere to the business principle of “Friendship, Equality, and Mutual Development”, continue to strengthen our supply chain management, and endeavour to enhance our information security and integrity standards to build a safe and robust leading enterprise in the pharmaceutical industry. We actively fulfil our social responsibilities and participate in a wide range of public welfare projects. We have continued to invest in various areas such as prevention and treatment of chronic diseases, industry assistance, education development, disaster relief and pet welfare, and encouraged our employees to actively participate in diversified voluntary activities. During the Year, the Group continued to promote the "Filial Piety Swallows" Charity Activities, which had a cumulative total of 89 activities and over 6,700 beneficiaries as at the end of the reporting period. Looking ahead to 2025, The United Laboratories will embark on a new chapter in the development. We will embrace change with an open and inclusive attitude, continue to consolidate our core competitiveness in the fields of innovative drugs and high-barrier complex pharmaceuticals, and deeply integrate ESG concepts into our corporate strategy. Through new technology and models of digitalisation and intelligence, we will enhance the Group's sustainable development capability. In addition to providing quality products and services to patients, we have been actively implementing the concept of green and low-carbon development, building a diversified development platform and insisting on the development of social welfare undertakings. Relying on our extensive corporate influence, we collaborate with our business partners to jointly build a sustainable industry ecosystem, thereby making a significant contribution to the realisation of the “Healthy China” strategy. as one of the leading companies in the domestic pharmaceutical industry, , Chairman Statement 3.1 Chairman Tsoi Hoi Shan Environmental, Social and Governance Report 2024 The United Laboratories International Holdings Limited